Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: A dual-target drug for the treatment of Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 5, 2015, Pages 1792-1807

  Duan, Songwei ^a,b   Guan, Xiaoyin ^a   Lin, Runxuan ^a   Liu, Xincheng ^a   Yan, Ying ^a   Lin, Ruibang ^a,b   Zhang, Tianqi ^a   Chen, Xueman ^a   Huang, Jiaqi ^a   Sun, Xicui ^c   Li, Qingqing ^a   Fang, Shaoliang ^d   Xu, Jun ^b   Yao, Zhibin ^a   Gu, Huaiyu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Guangzhou Brain Hospital   (China)

^d SHENZHEN UNIVERSITY   (China)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Amyloid protein; APP PS1 transgenic mice; MD simulation; Memory deficits; Silibinin

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BROXURIDINE; SILIBININ; CHOLINESTERASE INHIBITOR; SILYMARIN;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CIRCULAR DICHROISM; CONTROLLED STUDY; DOWN REGULATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE GUN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; WHOLE CELL PATCH CLAMP; ANIMAL; CHEMISTRY; DENTATE GYRUS; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; NERVE REGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PHYTOTHERAPY; PROTEINOSIS; SILYBUM MARIANUM; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOLINESTERASE INHIBITORS; DENTATE GYRUS; FEMALE; MALE; MICE, TRANSGENIC; MILK THISTLE; NERVE REGENERATION; PHYTOTHERAPY; PROTEIN AGGREGATION, PATHOLOGICAL; RATS, SPRAGUE-DAWLEY; SILYMARIN;

EID: 84933180138     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.02.002     Document Type: Article

References (64)

1. Adalbert R., Coleman M.P. Review: axon pathology in age-related neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 2013, 39:90-108.
2. Ahmed M., Davis J., Aucoin D., Sato T., Ahuja S., Aimoto S., Elliott J.I., Van Nostrand W.E., Smith S.O. Structural conversion of neurotoxic amyloid-β1-42 oligomers to fibrils. Nat. Struct. Mol. Biol. 2010, 17:561-567.
3. Agis-Torres A., Solhuber M., Fernandez M., Sanchez-Montero J.M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr. Neuropharmacol. 2014, 12:2-36.
4. Bartolini M., Bertucci C., Cavrini V., Andrisano V. β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65:407-416.
5. Bayer T.A., Wirths O. Review on the APP/PS1KI mouse model: intraneuronal Aβ accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav. 2008, 7:6-11.
6. Bayly C.I., Cieplak P., Cornell W., Kollman P.A. Awell-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J.Phys. Chem. 1993, 97:10269-10280.
7. Bloem B., Poorthuis R.B., Mansvelder H.D. Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity. Front. Neural Circuits 2014, 8:17.
8. Bourne Y., Taylor P., Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J. 2003, 22:1-12.
9. Case D., Darden T., Cheatham T., Simmerling C., Wang J., Duke R., Luo R., Walker R., Zhang W., Merz K. AMBER 11 2010, University of California, San Francisco 142.
10. Chong L.T., Duan Y., Wang L., Massova I., Kollman P.A. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14330-14335.
11. Crescenzi O., Tomaselli S., Guerrini R., Salvadori S., D'Ursi A.M., Temussi P.A., Picone D. Solution structure of the Alzheimer amyloid β-peptide (1-42) in an apolar microenvironment. Eur. J. Biochem. 2002, 269:5642-5648.
12. Crowley P.B., Golovin A. Cation-π interactions in protein-protein interfaces. Proteins 2005, 59:231-239.
13. Darden T., York D., Pedersen L. Particle mesh Ewald: an N{dot operator} log (N) method for Ewald sums in large systems. J.Chem. Phys. 1993, 98:10089.
14. Di Cesare Mannelli L., Zanardelli M., Failli P., Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J.Pain 2012, 13:276-284.
15. Deutsch J.A. The cholinergic synapse and the site of memory. Science 1971, 174:788-794.
16. Duan Y., Wu C., Chowdhury S., Lee M.C., Xiong G., Zhang W., Yang R., Cieplak P., Luo R., Lee T. Apoint-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J.Comput. Chem. 2003, 24:1999-2012.
17. Ellman G.L., Courtney K.D., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol 1961, 7:88-95.
18. Estrada L., Soto C. Disrupting-amyloid aggregation for alzheimer disease treatment. Curr. Top. Med. Chem. 2007, 7:115-126.
19. Faure A., Verret L., Bozon B., El Tannir E.T.N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol. Aging 2011, 32:407-418.
20. Fogolari F., Brigo A., Molinari H. Protocol for MM/PBSA molecular dynamics simulations of proteins. Biophys. J. 2003, 85:159-166.
21. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1997, 41:17-24.
22. Gu H., Jiang S.A., Campusano J.M., Iniguez J., Su H., Hoang A.A., Lavian M., Sun X., O'Dowd D.K. Cav2-type calcium channels encoded by cac regulate AP-independent neurotransmitter release at cholinergic synapses in adult Drosophila brain. J.Neurophysiol. 2009, 101:42-53.
23. Gu H., O'Dowd D.K. Whole cell recordings from brain of adult Drosophila. J.Vis. Exp. 2007, 6:248.
24. Gu H., O'Dowd D.K. Cholinergic synaptic transmission in adult Drosophila Kenyon cells in situ. J.Neurosci. 2006, 26:265-272.
25. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cel. Biol. 2007, 8:101-112.
26. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
27. Harel M., Sussman J., Krejci E., Bon S., Chanal P., Massoulie J., Silman I. Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. Proc. Natl. Acad. Sci. USA 1992, 89:10827-10831.
28. Herholz K. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:25-29.
29. Inestrosa N.C., Dinamarca M.C., Alvarez A. Amyloid-cholinesterase interactions. FEBS J. 2008, 275:625-632.
30. Isacson O., Seo H., Lin L., Albeck D., Granholm A.-C. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends. Neurosci. 2002, 25:79-84.
31. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J.Chem. Phys. 1983, 79:926.
32. Knecht V., Möhwald H., Lipowsky R. Conformational diversity of the fibrillogenic fusion peptide B18 in different environments from molecular dynamics simulations. J.Phys. Chem. B. 2007, 111:4161-4170.
33. Křen V., Walterova D. Silybin and silymarin-new effects and applications. Biomed. Pap. 2005, 149:29-41.
34. Kudin K., Burant J., Millam J., Iyengar S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N. Gaussian 03, Revision E. 01 2004, Gaussian Inc, Pittsburgh, PA.
35. Lührs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Döbeli H., Schubert D., Riek R. 3D structure of Alzheimer's amyloid-β (1-42) fibrils. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17342-17347.
36. Laursen B., Mørk A., Plath N., Kristiansen U., Bastlund J.F. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav. Brain Res. 2013, 240:146-152.
37. Lu P., Mamiya T., Lu L., Mouri A., Zou L., Nagai T., Hiramatsu M., Ikejima T., Nabeshima T. Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice. Br. J. Pharmacol. 2009, 157:1270-1277.
38. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J.Neurochem. 2008, 105:584-594.
39. Moolman D.L., Vitolo O.V., Vonsattel J.-P.G., Shelanski M.L. Dendrite and dendritic spine alterations in Alzheimer models. J.Neurocytol. 2004, 33:377-387.
40. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J.Comput. Chem. 1998, 19:1639-1662.
41. Mu Y., Gage F.H. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener. 2011, 6:85.
42. Muñoz F.J., Inestrosa N.C. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett. 1999, 450:205.
43. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
44. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999, 22:273-280.
45. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., Ehrhart J., Townsend K., Zeng J., Morgan D. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J.Neurosci. 2005, 25:8807-8814.
46. Ryckaert J.-P., Ciccotti G., Berendsen H.J. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J.Comput. Phys. 1977, 23:327-341.
47. Sanson B.t., Nachon F., Colletier J.-P., Froment M.-T., Toker L., Greenblatt H.M., Sussman J.L., Ashani Y., Masson P., Silman I. Crystallographic snapshots of nonaged and aged conjugates of soman with acetylcholinesterase, and of a ternary complex of the aged conjugate with pralidoxime. J.Med. Chem. 2009, 52:7593-7603.
48. Seabold G.K., Daunais J.B., Rau A., Grant K.A., Alvarez V.A. DiOLISTIC labeling of neurons from rodent and non-human primate brain slices. J.Vis. Exp. 2010, 6:41.
49. Shao B.Y., Xia Z., Xie Q., Ge X.X., Zhang W.W., Sun J., Jiang P., Wang H., Le W.D., Qiu Z.B., Lu Y., Chen H.Z. Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice. CNS Neurosci. Ther. 2014, 20:165-171.
50. Skovronsky D.M., Doms R.W., Lee V.M.-Y. Detection of a novel intraneuronal pool of insoluble amyloid β protein that accumulates with time in culture. J.Cell Biol. 1998, 141:1031-1039.
51. Sreerama N., Woody R.W. Computation and analysis of protein circular dichroism spectra. Methods Enzymol. 2004, 383:318-351.
52. Staffend N.A., Meisel R.L. DiOlistic labeling in fixed brain slices: phenotype, morphology, and dendritic spines. Curr. Protoc. Neurosci. 2011, Chapter 2. Unit 2.13-2.13.15.
53. Steiner T., Koellner G. Hydrogen bonds with π-acceptors in proteins: frequencies and role in stabilizing local 3D structures. J.Mol. Biol. 2001, 305:535-557.
54. Tapia-Arancibia L., Aliaga E., Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res. Rev. 2008, 59:201-220.
55. Tarus B., Straub J.E., Thirumalai D. Dynamics of Asp23-Lys28 salt-bridge formation in Aβ10-35 monomers. J.Am. Chem. Soc. 2006, 128:16159-16168.
56. Terry A.V., Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 2003, 306:821-827.
57. Tota S., Kamat P.K., Shukla R., Nath C. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav. Brain Res. 2011, 221:207-215.
58. Viet M.H., Ngo S.T., Lam N.S., Li M.S. Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity. J.Phys. Chem. B. 2011, 115:7433-7446.
59. Vorhees C.V., Williams M.T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1:848-858.
60. Wang J., Wolf R.M., Caldwell J.W., Kollman P.A., Case D.A. Development and testing of a general amber force field. J.Comput. Chem. 2004, 25:1157-1174.
61. Wintjens R., Liévin J., Rooman M., Buisine E. Contribution of cation-π interactions to the stability of protein-DNA complexes. J.Mol. Biol. 2000, 302:393-408.
62. Yan Z., Feng J. Alzheimers disease: interactions between cholinergic functions and beta-amyloid. Curr. Alzheimer Res. 2004, 1:241-248.
63. Yang C., Zhu X., Li J., Shi R. Exploration of the mechanism for LPFFD inhibiting the formation of β-sheet conformation of Aβ(1-42) in water. J. Mol. Model. 2010, 16:813-821.
64. Yin F., Liu J., Ji X., Wang Y., Zidichouski J., Zhang J. Silibinin: a novel inhibitor of Aβ aggregation. Neurochem. Int. 2011, 58:399-403.